Inclusion Criteria:

- Patients must have histologically documented invasive epithelial ovarian,
extraovarian, fallopian tube or endometrial carcinoma.

- Patients must have persistent or recurrent disease after standard debulking/staging
surgery and conventional therapy.

- Patients must have evidence of intraabdominal disease; disease may be measurable or
nonmeasurable.

- Patients must have a GOG performance status of 0, 1, or 2, and have a life expectancy
of greater than 3 months.

- Patients must have adequate hematologic, renal, and hepatic function defined as:

- WBC > 3,000 ul

- Granulocytes > 1,500 ul

- Platelets > 100,000

- Creatinine clearance > 80 mg/dl or serum creatinine > 2.0

- Serum transaminases < 2.5 x upper limits of normal

- Normal serum bilirubin

- PT/PTT/INR < 1.5 x institutional ULN

- O2 saturation > or = 92 %

- Patients must be 19 years or older and must have signed informed consent

Exclusion Criteria:

- Patients with epithelial tumors of low malignant potential, stromal tumors and germ
cell tumors of the ovary are ineligible to participate in the study.

- Patients with the only site of disease located beyond the abdominal cavity are
ineligible to participate in the study.

- Patients who are pregnant or lactating are ineligible to participate in the study.

- Patients with a GOG performance status of 3 or 4 are ineligible to participate in the
study.

- Patients with active heart disease (characterized by angina, unstable arrhythmia,
congestive heart failure or EF < 55%, pulmonary hyper- tension, active or chronic
debilitating pulmonary disease(i.e., active pneumonia, severe COPD, pulmonary edema,
O2 saturation < 92%), or coagulation disorders (i.e. bleeding disorders, or on
therapeutic anti- coagulants)